A DNA Methyltransferase Inhibitor, 5‐Aza‐2′‐Deoxycytidine, Exacerbates Neurotoxicity and Upregulates Parkinson's Disease‐Related Genes in Dopaminergic Neurons. (26th February 2013)
- Record Type:
- Journal Article
- Title:
- A DNA Methyltransferase Inhibitor, 5‐Aza‐2′‐Deoxycytidine, Exacerbates Neurotoxicity and Upregulates Parkinson's Disease‐Related Genes in Dopaminergic Neurons. (26th February 2013)
- Main Title:
- A DNA Methyltransferase Inhibitor, 5‐Aza‐2′‐Deoxycytidine, Exacerbates Neurotoxicity and Upregulates Parkinson's Disease‐Related Genes in Dopaminergic Neurons
- Authors:
- Wang, Yong
Wang, Xuan
Li, Ran
Yang, Zhao‐Fei
Wang, Yi‐Zheng
Gong, Xiao‐Li
Wang, Xiao‐Min - Abstract:
- <abstract abstract-type="main" id="cns12059-abs-0001"> <title>Summary</title> <sec id="cns12059-sec-0001" sec-type="section"> <title>Aims</title> <p>To investigate effects of DNA methyltransferase (DNMT) inhibitors on dopaminergic neurons and its underlied mechanism.</p> </sec> <sec id="cns12059-sec-0002" sec-type="section"> <title>Methods</title> <p>The DNMT inhibitor 5‐aza‐2′‐deoxycytidine (5‐aza‐dC) was tested in cultured dopaminergic cells. Cell viability and apoptosis were assayed with 5‐aza‐dC alone. Neurotoxicity of 1‐methyl‐4‐phenylpyridinium (MPP<sup>+</sup>), 6‐hydroxydopamine or rotenone was also assayed with 5‐aza‐dC pretreatment. And mRNA levels of several key PD‐related genes were examined by semiquantitative RT‐PCR. Furthermore, CpG methylation of <italic>α‐synuclein</italic> promoter was examined by bisulfite sequencing.</p> </sec> <sec id="cns12059-sec-0003" sec-type="section"> <title>Results</title> <p>5‐aza‐dC resulted in decreased cell viability and increased apoptosis in dopaminergic neuronal cells. Pretreatment with 5‐aza‐dC exacerbated neurotoxic damage to dopaminergic neurons induced by MPP<sup>+</sup>, 6‐hydroxydopamine or rotenone. 5‐aza‐dC also induced transcriptional upregulation of the key PD‐related genes <italic>tyrosine hydroxylase</italic> and <italic>α‐synuclein</italic>. And demethylation of CpG in <italic>α‐synuclein</italic> promoter was also induced by 5‐aza‐dC and MPP<sup>+</sup>.</p> </sec> <sec id="cns12059-sec-0004"<abstract abstract-type="main" id="cns12059-abs-0001"> <title>Summary</title> <sec id="cns12059-sec-0001" sec-type="section"> <title>Aims</title> <p>To investigate effects of DNA methyltransferase (DNMT) inhibitors on dopaminergic neurons and its underlied mechanism.</p> </sec> <sec id="cns12059-sec-0002" sec-type="section"> <title>Methods</title> <p>The DNMT inhibitor 5‐aza‐2′‐deoxycytidine (5‐aza‐dC) was tested in cultured dopaminergic cells. Cell viability and apoptosis were assayed with 5‐aza‐dC alone. Neurotoxicity of 1‐methyl‐4‐phenylpyridinium (MPP<sup>+</sup>), 6‐hydroxydopamine or rotenone was also assayed with 5‐aza‐dC pretreatment. And mRNA levels of several key PD‐related genes were examined by semiquantitative RT‐PCR. Furthermore, CpG methylation of <italic>α‐synuclein</italic> promoter was examined by bisulfite sequencing.</p> </sec> <sec id="cns12059-sec-0003" sec-type="section"> <title>Results</title> <p>5‐aza‐dC resulted in decreased cell viability and increased apoptosis in dopaminergic neuronal cells. Pretreatment with 5‐aza‐dC exacerbated neurotoxic damage to dopaminergic neurons induced by MPP<sup>+</sup>, 6‐hydroxydopamine or rotenone. 5‐aza‐dC also induced transcriptional upregulation of the key PD‐related genes <italic>tyrosine hydroxylase</italic> and <italic>α‐synuclein</italic>. And demethylation of CpG in <italic>α‐synuclein</italic> promoter was also induced by 5‐aza‐dC and MPP<sup>+</sup>.</p> </sec> <sec id="cns12059-sec-0004" sec-type="section"> <title>Conclusions</title> <p>This DNMT inhibitor might influence pathogenesis of PD. And demethylation induced by DNMT inhibitor might contribute to dopaminergic neuron death, by increasing vulnerability of dopaminergic neurons to neurotoxins and by misregulating transcription of key PD‐related genes. Our data also suggested DNMT inhibitors may cause multiple effects on dopaminergic neurons.</p> </sec> </abstract> … (more)
- Is Part Of:
- CNS neuroscience & therapeutics. Volume 19:Number 3(2013)
- Journal:
- CNS neuroscience & therapeutics
- Issue:
- Volume 19:Number 3(2013)
- Issue Display:
- Volume 19, Issue 3 (2013)
- Year:
- 2013
- Volume:
- 19
- Issue:
- 3
- Issue Sort Value:
- 2013-0019-0003-0000
- Page Start:
- 183
- Page End:
- 190
- Publication Date:
- 2013-02-26
- Subjects:
- Neuropharmacology -- Periodicals
Central nervous system -- Diseases -- Effect of drugs on -- Periodicals
612.8 - Journal URLs:
- http://www.blackwell-synergy.com/loi/cnsnt ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cns.12059 ↗
- Languages:
- English
- ISSNs:
- 1755-5930
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9830.140000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3889.xml